Skip to main content
SpringerLink
Log in

Exenatide extended-release pre-filled pen (Bydureon® BCise®): a profile of its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The Bydureon® BCise® pre-filled pen was developed largely to simplify self-administration of exenatide extended-release for patients with type 2 diabetes, being comfortable and intuitive to use, with easy-to-mix medication, sterile and safe needle containment, reliable/accurate dose delivery, and indicators of complete dose delivery and device use. Subcutaneous self-injection with Bydureon BCise involves three simple key steps (mixing, unlocking and pressing against the skin to inject) and has a needle that remains hidden, ensuring sterility and reducing the likelihood of accidental injury. In a single-injection study, the Bydureon BCise pre-filled pen was largely considered ‘easy’/‘very easy’ to use, and had a high rate of successful injection completion, including among lay users with dexterity or visual impairment. As an add-on to diet and exercise or oral glucose-lowering therapy, Bydureon BCise once weekly improved glycaemic control and provided glycaemic benefits over subcutaneous twice-daily exenatide and oral once-daily sitagliptin. Bydureon BCise was also generally well tolerated and appeared to have a better gastrointestinal profile, but more injection-site reactions, than twice-daily exenatide, and a less favourable gastrointestinal profile, but greater patient satisfaction, than sitagliptin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Faerch K, Torekov SS, Vistisen D, et al. GLP-1 response to oral glucose Is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study. Diabetes. 2015;64(7):2513–25.

    Article  CAS  PubMed  Google Scholar 

  2. Lee S, Lee DY. Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Ann Pediatr Endocrinol Metab. 2017;22(1):15–26.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317–32.

    Article  CAS  PubMed  Google Scholar 

  4. Samson SL, Garber AJ. A plethora of GLP-1 agonists: decisions about what to use and when. Curr Diabetes Rep. 2016;16(12):120.

    Article  CAS  Google Scholar 

  5. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701.

    Article  PubMed  Google Scholar 

  6. American Diabetes Association. Pharmacological approaches glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S73–85.

    Article  Google Scholar 

  7. International Diabetes Federation. IDF clinical practice recommendations for managing type 2 diabetes in primary care. Brussels: International Diabetes Federation; 2017.

    Google Scholar 

  8. Torekov SS. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL. Cardiovasc Res. 2018;114(10):e70–1.

    Article  CAS  PubMed  Google Scholar 

  9. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.

    Article  CAS  PubMed  Google Scholar 

  10. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.

    Article  CAS  PubMed  Google Scholar 

  11. Byetta (exenatide) solution for injection in prefilled-pen: summary of product characteristics (EU).Södertälje (Sweden): AstraZeneca AB; 2018.

  12. Byetta (exenatide) injection : US prescribing information. Wilmington (DE): AstraZeneca Phamaceuticals LP; 2015.

  13. Bydureon 2 mg powder and solvent for prolonged-release suspension for injection. Bydureon summary of product characteristics (EU). Södertälje (Sweden): AstraZeneca AB; 2018. p. 2–20.

  14. Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen. Bydureon summary of product characteristics (EU). Södertälje (Sweden): AstraZeneca AB; 2018. p. 21–39.

  15. Bydureon® (exenatide extended-release) for injectable suspension, for subcutaneous use: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2018.

  16. DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(d, l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. American Diabetes Association. Introduction: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S1–2.

    Google Scholar 

  18. American Diabetes Association. Improving care and promoting health in populations: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S7–12.

    Article  Google Scholar 

  19. Garcia-Perez LE, Alvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–94.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Cooke CE, Lee HY, Tong YP, et al. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26(1):231–8.

    Article  PubMed  Google Scholar 

  21. Spain CV, Wright JJ, Hahn RM, et al. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin Ther. 2016;38(7):1653–64.e1.

    Article  PubMed  Google Scholar 

  22. Frid A, Hirsch L, Gaspar R, et al. New injection recommendations for patients with diabetes. Diabetes Metab. 2010;36(Suppl 2):S3–18.

    Article  PubMed  Google Scholar 

  23. Bydureon® BCise™ (exenatide extended-release) injectable suspension, for subcutaneous use : US prescribing information. Wilmington (DE): AstraZeneca Phamaceuticals LP; 2017.

  24. Bydureon 2 mg prolonged-release suspension for injection in pre-filled pen (BCise). Bydureon summary of product characteristics (EU). Södertälje (Sweden): AstraZeneca AB; 2018. p. 40–59.

  25. LaRue S, Springer J, Noderer M, et al. Evaluation of the use of exenatide once-weekly suspension autoinjector among patients with type 2 diabetes mellitus and health care professionals. J Diabetes Sci Technol. 2018. https://doi.org/10.1177/1932296818798376.

    Article  PubMed  Google Scholar 

  26. Buss N, Ryan P, Baughman T, et al. Nonclinical safety and pharmacokinetics of Miglyol 812: a medium chain triglyceride in exenatide once weekly suspension. J Appl Toxicol. 2018;38(10):1293–301.

    Article  CAS  PubMed  Google Scholar 

  27. Wysham CH, Rosenstock J, Vetter ML, et al. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(1):165–72.

    Article  CAS  PubMed  Google Scholar 

  28. Gadde KM, Vetter ML, Iqbal N, et al. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017;19(7):979–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The manuscript was reviewed by: S. Chinwong, Department of Pharmaceutical Care, Chiang Mai University, Chiang Mai, Thailand; A.D. Mooradian, Department of Medicine, University of Florida College of Medicine, Jacksonville, FL, USA; W.M. Valencia, Geriatric Research, Education and Clinical Center (GRECC), Miami VA Healthcare System, Miami, FL. USA. During the peer review process, AstraZeneca, the marketing-authorization holder of Bydureon® BCise®, was offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Emma D. Deeks

Authors
  1. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma D. Deeks.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

E. D. Deeks is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deeks, E.D. Exenatide extended-release pre-filled pen (Bydureon® BCise®): a profile of its use. Drugs Ther Perspect 35, 51–57 (2019). https://doi.org/10.1007/s40267-018-00597-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-00597-2

Search

Navigation